Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a leading biotechnology company in the emerging field of psychedelic medicine, with a strong focus on developing treatments for mental health disorders. Their pioneering approach, using a proprietary synthetic psilocybin formulation alongside psychological support, has shown promising results in multiple clinical trials for treatment-resistant depression. With Breakthrough Therapy designation from the FDA and ongoing clinical trials for other indications, the company is well-positioned to be a leader in the psychedelic therapeutics space. We see room for multiple winners in this emerging class and believe CMPS has a strong potential for revenue growth, particularly in the treatment-resistant depression market. The company's strong financials and pipeline of other potential indications such as PTSD and anorexia nervosa also contribute to our positive outlook.

Bears say

Compass Pathways is valued at $21 per share, based on a DCF analysis of its current drug development and potential market success. The company's risk-adjusted COMP360 revenues in the treatment-resistant depression market and modest credit for its PTSD program contribute to its valuation. However, the potential for regulatory and IP exclusivity issues, as well as challenges in defining reimbursement pathways, could negatively impact the company's future success and result in a decline in stock value.

COMPASS Pathways (CMPS) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 11 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.